Literature DB >> 26821814

Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Ashley D Chadha1, Isaac P Thomsen2, Natalia Jimenez-Truque2, Nicole R Soper2, Lauren S Jones2, Andrew G Sokolow1, Victor J Torres3, C Buddy Creech2.   

Abstract

BACKGROUND: Staphylococcus aureus is one of the earliest bacterial pathogens to colonize the lungs of children with cystic fibrosis and is an important contributor to pulmonary exacerbations. The adaptive host response to S. aureus in cystic fibrosis remains inadequately defined and has important implications for pathogenesis and potential interventions. The objectives of this study were to determine the functional antibody response to select staphylococcal exotoxins (LukAB, alpha-hemolysin, and PVL) in children with cystic fibrosis and to evaluate the relationship of this response with pulmonary exacerbations.
METHODS: Fifty children with cystic fibrosis were enrolled and followed prospectively for 12months. Clinical characteristics and serologic profiles were assessed at routine visits and during pulmonary exacerbations, and functional antibody assessments were performed to measure neutralization of LukAB-mediated cytotoxicity.
RESULTS: For each antigen, geometric mean titers were significantly higher if S. aureus was detected at the time of exacerbation. For LukAB, geometric mean titers were significantly higher at exacerbation follow-up compared to titers during the exacerbation, consistent with expression during human disease, and the humoral response capably neutralized LukAB-mediated cytotoxicity. Moreover, the presence of a positive S. aureus culture during a pulmonary exacerbation was associated with 31-fold higher odds of having a LukA titer ≥1:160, suggesting potential diagnostic capability of this assay.
CONCLUSIONS: The leukotoxin LukAB is expressed by S. aureus and recognized by the human adaptive immune response in the setting of pulmonary infection in cystic fibrosis. Anti-LukAB antibodies were not only predictive of positive staphylococcal culture during exacerbation, but also functional in the neutralization of this toxin.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Exotoxins; LukAB; Serology; Staphylococcus aureus

Mesh:

Substances:

Year:  2016        PMID: 26821814      PMCID: PMC4959994          DOI: 10.1016/j.jcf.2015.12.023

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  29 in total

1.  Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

Authors:  O Ciofu; T D Petersen; P Jensen; N Høiby
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

3.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

4.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

5.  Antibodies against superantigenic exotoxins produced by Staphylococcus aureus in sera from mothers and their infants' cord blood.

Authors:  Naoto Takahashi; Minako Hattori; Keishi Miwa; Hiroshi Nishida
Journal:  Am J Perinatol       Date:  2006-09-26       Impact factor: 1.862

6.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

7.  Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians.

Authors:  B Shopsin; B Mathema; P Alcabes; B Said-Salim; G Lina; A Matsuka; J Martinez; B N Kreiswirth
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils.

Authors:  Ashley L DuMont; Pauline Yoong; Bas G J Surewaard; Meredith A Benson; Reindert Nijland; Jos A G van Strijp; Victor J Torres
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

9.  Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1.

Authors:  Ashley L DuMont; Pauline Yoong; Christopher J Day; Francis Alonzo; W Hayes McDonald; Michael P Jennings; Victor J Torres
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

Review 10.  Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors?

Authors:  François Vandenesch; G Lina; Thomas Henry
Journal:  Front Cell Infect Microbiol       Date:  2012-02-16       Impact factor: 5.293

View more
  8 in total

1.  Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action.

Authors:  Isaac P Thomsen; Gopal Sapparapu; David B A James; James E Cassat; Meera Nagarsheth; Nurgun Kose; Nicole Putnam; Kristina M Boguslawski; Lauren S Jones; James B Wood; Clarence B Creech; Victor J Torres; James E Crowe
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

2.  Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).

Authors:  James B Wood; Lauren S Jones; Nicole R Soper; Meera Nagarsheth; C Buddy Creech; Isaac P Thomsen
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.

Authors:  Sibylle Junge; Dennis Görlich; Martijn den Reijer; Bärbel Wiedemann; Burkhard Tümmler; Helmut Ellemunter; Angelika Dübbers; Peter Küster; Manfred Ballmann; Cordula Koerner-Rettberg; Jörg Große-Onnebrink; Eberhardt Heuer; Wolfgang Sextro; Jochen G Mainz; Jutta Hammermann; Joachim Riethmüller; Ute Graepler-Mainka; Doris Staab; Bettina Wollschläger; Rüdiger Szczepanski; Antje Schuster; Friedrich-Karl Tegtmeyer; Sivagurunathan Sutharsan; Alexandra Wald; Jerzy-Roch Nofer; Willem van Wamel; Karsten Becker; Georg Peters; Barbara C Kahl
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

4.  Antibody-based intervention against the pore-forming toxins of Staphylococcus aureus.

Authors:  Isaac P Thomsen
Journal:  Virulence       Date:  2018-12-31       Impact factor: 5.882

Review 5.  Epidemiological and Clinical Evidence for the Role of Toxins in S. aureus Human Disease.

Authors:  Monique R Bennett; Isaac P Thomsen
Journal:  Toxins (Basel)       Date:  2020-06-19       Impact factor: 4.546

6.  Staphylococcus aureus Pathogenicity in Cystic Fibrosis Patients-Results from an Observational Prospective Multicenter Study Concerning Virulence Genes, Phylogeny, and Gene Plasticity.

Authors:  Jonas Lange; Kathrin Heidenreich; Katharina Higelin; Kristina Dyck; Vanessa Marx; Christian Reichel; Willem van Wamel; Martijn den Reijer; Dennis Görlich; Barbara C Kahl
Journal:  Toxins (Basel)       Date:  2020-04-26       Impact factor: 4.546

Review 7.  Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.

Authors:  Lloyd S Miller; Vance G Fowler; Sanjay K Shukla; Warren E Rose; Richard A Proctor
Journal:  FEMS Microbiol Rev       Date:  2020-01-01       Impact factor: 16.408

8.  Adoptive Transfer of Serum Samples From Children With Invasive Staphylococcal Infection and Protection Against Staphylococcus aureus Sepsis.

Authors:  Chih-Ming Tsai; Nicole Soper; Monique Bennett; Jonathan K Fallon; Ashlin R Michell; Galit Alter; George Y Liu; Isaac Thomsen
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.